Literature DB >> 2451115

The interaction between D-2 dopamine receptors and GTP-binding proteins.

K Ohara1, K Haga, G Berstein, T Haga, A Ichiyama, K Ohara1.   

Abstract

D-2 dopamine receptors were solubilized from porcine striatal membranes with 0.3% sodium cholate/1 M NaCl and separated from the bulk of the guanine nucleotide-binding regulatory proteins (G-proteins) by Ultrogel AcA34 gel filtration chromatography. The partially purified D-2 receptors were reconstituted in phospholipid vesicles with Gi or Go purified from porcine brain. The dissociation constant (Kd) of the D-2 receptors in the reconstituted vesicles for [3H]spiperone binding was 82-89 pm, which was not affected by the presence or absence of G-proteins. The displacement curve for [3H]spiperone/dopamine was analyzed, assuming that there are two populations of binding sites. The Kd values for the binding sites with high affinity for agonists (HAS) and that for the binding sites with low affinity for agonists (LAS) were approximately 1 microM and 100 microM, respectively. The proportion of HAS was 8% when the receptor preparation was reconstituted into phospholipid vesicles without G-proteins, but it increased to 58-64% with increasing G-protein concentrations. The potency of Go was a little higher than that of Gi. The proportion of HAS in the presence of G-proteins decreased to about 11% on addition of GTP. When G-proteins were treated with islet-activating protein, GTP-sensitive HAS were not observed. These results indicate that at least 50% of the partially purified D-2 receptors interact with both Gi and Go.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451115

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Coupling of D2 dopamine receptors to G-proteins in solubilized preparations of bovine caudate nucleus.

Authors:  J A Chazot; P G Strange
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

Review 2.  Drugs and receptors. An overview of the current state of knowledge.

Authors:  T Kenakin
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 3.  Pharmacological and molecular basis for dopamine D-2 receptor diversity.

Authors:  M Memo
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

4.  Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor.

Authors:  Cecilea C Clayton; Prashant Donthamsetti; Nevin A Lambert; Jonathan A Javitch; Kim A Neve
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

5.  Cloning of ligand-specific cell lines via gene transfer: identification of a D2 dopamine receptor subtype.

Authors:  R D Todd; T S Khurana; P Sajovic; K R Stone; K L O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

6.  Mono- and divalent cations modulate the affinities of brain D1 and D2 receptors for dopamine by a mechanism independent of receptor coupling to guanyl nucleotide binding proteins.

Authors:  S Urwyler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

7.  Modulation of secretion by dopamine involves decreases in calcium and nicotinic currents in bovine chromaffin cells.

Authors:  J M Sontag; P Sanderson; M Klepper; D Aunis; K Takeda; M F Bader
Journal:  J Physiol       Date:  1990-08       Impact factor: 5.182

8.  Vanadate inhibits agonist binding to D2 dopamine receptor.

Authors:  Z Elazar; S Fuchs
Journal:  J Mol Neurosci       Date:  1991       Impact factor: 3.444

9.  Guanine nucleotide binding proteins mediate D2 dopamine receptor activation of a potassium channel in rat lactotrophs.

Authors:  L C Einhorn; G S Oxford
Journal:  J Physiol       Date:  1993-03       Impact factor: 5.182

10.  High Sensitivity Mapping of Cortical Dopamine D2 Receptor Expressing Neurons.

Authors:  Jivan Khlghatyan; Clémentine Quintana; Martin Parent; Jean-Martin Beaulieu
Journal:  Cereb Cortex       Date:  2019-08-14       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.